Redhill Biopharma
RDHL
36 hedge funds and large institutions have $45.9M invested in Redhill Biopharma in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 9 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
5% less funds holding
Funds holding: 38 → 36 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
22% less capital invested
Capital invested by funds: $59.1M → $45.9M (-$13.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$8.51M |
| 2 |
II
Ibex Investors
Denver,
Colorado
|
+$3.16M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.53M |
| 4 |
Millennium Management
New York
|
+$950K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$919K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.76M |
| 2 |
Renaissance Technologies
New York
|
-$1.23M |
| 3 |
KC
Kepos Capital
New York
|
-$759K |
| 4 |
JP Morgan Chase
New York
|
-$652K |
| 5 |
CHAM
Clear Harbor Asset Management
Stamford,
Connecticut
|
-$323K |
RDHL Hedge Fund Activity: Q4 2018 in Review
36 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2018, worth a combined $45.9M — down 22% from $59.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RDHL and 7 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 13 added.
The largest buyer was Disciplined Growth Investors, adding an estimated $8.51M. The largest seller was OrbiMed, cutting an estimated $1.76M.
- 36 institutional investors held Redhill Biopharma (RDHL) as of Q4 2018, down from 38 in Q3 2018.
- Funds reported $45.9M of Redhill Biopharma stock for Q4 2018, down 22% quarter-over-quarter.
- 7 funds opened new Redhill Biopharma positions in Q4 2018 and 9 closed out, a net change of -2 holders.
- The largest Redhill Biopharma buyer in Q4 2018 was Disciplined Growth Investors, an estimated $8.51M added.
- The largest Redhill Biopharma seller in Q4 2018 was OrbiMed, an estimated $1.76M sold.
Based on aggregated 13F filings for Q4 2018.